StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3049% above fair value
$47.29−3.73 (-7.31%)

Close on Nov 17, 2026Market cap $1.41BP/E –Yield –

GeneDx revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

GeneDx's revenue for the twelve months ending Jun 30, 2026 was $454.43M, up 25.4% year over year. For fiscal 2025 it was $427.54M, up 40.0% from the year before. The highest annual figure on record is $427.54M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$427.54M+40.0%
FY2024Dec 31, 2024$305.45M+50.8%
FY2023Dec 31, 2023$202.57M-13.7%
FY2022Dec 31, 2022$234.69M+10.6%
FY2021Dec 31, 2021$212.20M+18.3%
FY2020Dec 31, 2020$179.32M-8.6%
FY2019Dec 31, 2019$196.17M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$114.44M+11.4%
Q1 FY2026Mar 31, 2026$102.25M+17.4%
Q4 FY2025Dec 31, 2025$120.99M+26.5%
Q3 FY2025Sep 30, 2025$116.74M+51.9%
Q2 FY2025Jun 30, 2025$102.69M+45.6%
Q1 FY2025Mar 31, 2025$87.12M+39.6%
Q4 FY2024Dec 31, 2024$95.64M+66.6%
Q3 FY2024Sep 30, 2024$76.87M+44.2%
Q2 FY2024Jun 30, 2024$70.51M+44.8%
Q1 FY2024Mar 31, 2024$62.42M+44.7%
Q4 FY2023Dec 31, 2023$57.42M-6.4%
Q3 FY2023Sep 30, 2023$53.30M-36.0%
Q2 FY2023Jun 30, 2023$48.71M+34.7%
Q1 FY2023Mar 31, 2023$43.14M-20.0%
Q4 FY2022Dec 31, 2022$61.35M+6.1%
Q3 FY2022Sep 30, 2022$83.23M+92.8%
Q2 FY2022Jun 30, 2022$36.17M-23.1%
Q1 FY2022Mar 31, 2022$53.94M-16.0%
Q4 FY2021Dec 31, 2021$57.80M-9.6%
Q3 FY2021Sep 30, 2021$43.18M+11.8%
Q2 FY2021Jun 30, 2021$47.02M+56.2%
Q1 FY2021Mar 31, 2021$64.20M+37.6%
Q4 FY2020Dec 31, 2020$63.96M–
Q3 FY2020Sep 30, 2020$38.61M–
Q2 FY2020Jun 30, 2020$30.10M–
Q1 FY2020Mar 31, 2020$46.66M–

More GeneDx figures

See a number that looks wrong?